title: Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by nodules, abscesses and sinus tracts, primarily affecting the intertriginous areas. The occlusion of the upper part of the folliculopilosebaceous unit, leading to rupture of the sebofollicular canal with the consequent development of perifollicular lympho-histiocytic inflammation, is believed to be the initial pathogenic event in HS. Giving the chronic nature of HS, its destructive impact on social, working and daily life of patients, its management is often frustrating both for patients and physicians. The HS treatment choices are influenced by disease severity and its individual subjective impact. In this article, the Board of the Italian Society of Dermatology and Venereology (SIDeMaST) on HS has prepared a document focusing on the role of biologic drugs (anti-TNF-α) in HS management, providing also a flow-chart for HS handling and the inclusion and exclusion criteria for HS treatment with anti-TNF-α.
authors.affiliation: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy - mat24@libero.it.
authors.forename: M
authors.initials: M
authors.lastname: Megna
authors.forename: V
authors.initials: V
authors.lastname: Bettoli
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
authors.forename: A
authors.initials: A
authors.lastname: Chiricozzi
authors.forename: L
authors.initials: L
authors.lastname: Naldi
authors.forename: A
authors.initials: A
authors.lastname: Virgili
authors.forename: G
authors.initials: G
authors.lastname: Girolomoni
authors.forename: G
authors.initials: G
authors.lastname: Monfrecola
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D000068800:Etanercept / Q000627:therapeutic use*; D017497:Hidradenitis Suppurativa / Q000145:classification / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D017255:Acitretin; D000068800:Etanercept